Dulan Lokuwithana
Senior Healthcare News Editor at Seeking Alpha
🧡 Senior healthcare news editor @seekingalpha – connecting the dots between healthcare and Wall Street; Ex-Moody's, 🎓Edu.: CFA (US), CIMA (UK) & USJP 🇱🇰
Articles
-
1 week ago |
seekingalpha.com | Dulan Lokuwithana
The U.S. Senate’s version of the GOP tax bill has no plans to impose funding cuts to Medicare health insurance program but includes a proposal to lower the Medicaid provider tax to 3.5%, multiple news outlets reported Monday.
-
1 week ago |
seekingalpha.com | Dulan Lokuwithana
Pgiam/iStock via Getty ImagesHinge Health (NYSE:HNGE) shares traded higher on Monday after Wall Street analysts launched its coverage with bullish views, citing its growth potential as the digital health company’s post-IPO quiet period ended. Several brokerages, including Bank of America and Needham, issued buy-equivalent ratings
-
1 week ago |
seekingalpha.com | Dulan Lokuwithana
Arkadiusz WargułaAttorneys general representing all 50 U.S. states as well as Washington, D.C., and four U.S. territories on Monday agreed to a $7.4B deal to settle opioid-related litigation against Purdue Pharma, the company behind the painkiller OxyContin. The agreement comes after
-
1 week ago |
seekingalpha.com | Dulan Lokuwithana
Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its gene therapy for Duchenne muscular dystrophy. The Cambridge, Massachusetts-based biotech has already
-
1 week ago |
seekingalpha.com | Dulan Lokuwithana
Michael Vi/iStock Editorial via Getty ImagesAbbVie (NYSE:ABBV) announced Monday a setback for a Phase 3 trial designed to test its Roche (OTCQX:RHHBF)-partnered leukemia therapy venetoclax as part of a combination regimen against blood cancer myelodysplastic syndrome (MDS). Citing data from its global Phase 3 VERONA
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 287
- Tweets
- 4K
- DMs Open
- No
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset $LQDA $INSM $UTHR Gift Link: https://t.co/trduAKukWH (https://t.co/iU144gIbQQ)
RT @ohadhammer: Interesting slides on the PD1 market from Morgan Stanley, especially how each tumor type is dominated by different drugs d…
$BMY $HALO https://t.co/N7rge9KXnT